Prostate cancer treatment under the microscope: does dose matter?
NCT ID NCT06700057
First seen Feb 01, 2026 · Last updated Apr 25, 2026 · Updated 13 times
Summary
This study looks at a radioactive drug (177Lu-PSMA-617) used for advanced prostate cancer that has spread. Researchers want to measure how much radiation the tumor and healthy organs receive, and see if higher doses lead to better response or more side effects. About 50 adults with metastatic, castration-resistant prostate cancer will participate. The goal is to improve treatment safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Bergonie
RECRUITINGBordeaux, 33600, France
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.